Ixazomib inhibits myeloma cell proliferation by targeting UBE2K

Wang, Qingqing; Dong, Zhi-Gao; Su, Junnan; Huang, Jinmei; Xiao, Peipei; Tian, Lihong; Chen, Yong Q.; Ma, Lili; Chen, Xuyan

doi:10.1016/j.bbrc.2021.02.048

Cited by 10 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In types of human cancer, UBE2K is reported to be upregulated in gastric cancer (GC) and a high expression of UBE2K is associated with poor prognosis in patients with GC (16). It is also reported that UBE2K, acting as an oncogene, is downregulated by ixazomib and further demonstrated to be involved in ixazomib-induced cell apoptosis, cell cycle arrest, reactive oxygen species production and inhibition of myeloma cell proliferation (15).…”

Section: Discussionmentioning

confidence: 99%

“…For instance, UBE2K serves important roles in nervous system diseases, including Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) (11)(12)(13)(14). Findings from previous studies have also demonstrated that UBE2K serves vital roles in tumors and can be a target in cancer therapy (15,16). For example, ixazomib exhibits antitumor potential by targeting UBE2K in myeloma cells (15) and the overexpression of UBE2K promotes gastric cancer progression in vitro and in vivo (16).…”

Section: Introductionmentioning

confidence: 99%

“…Findings from previous studies have also demonstrated that UBE2K serves vital roles in tumors and can be a target in cancer therapy (15,16). For example, ixazomib exhibits antitumor potential by targeting UBE2K in myeloma cells (15) and the overexpression of UBE2K promotes gastric cancer progression in vitro and in vivo (16). However, its functions in PDAC remain to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma

Lei

et al. 2023

Int J Oncol

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a noteworthy malignant carcinoma with an unsatisfactory prognosis attributed to late diagnosis. Ubiquitin-conjugating enzyme E2K (UBE2K) has been found to serve important roles in a number of diseases. However, its function and the exact molecular mechanism of UBE2K in PDAC remain to be elucidated. The present study discovered that UBE2K was expressed at high levels and indicated the poor prognosis of patients with PDAC. Following this, the CCK-8, colony formation, and sphere formation assays showed that UBE2K promoted proliferation and the stemness phenotype of PDAC cells in vitro. Evidence from subcutaneous tumor-bearing nude mice experiments further confirmed that UBE2K enhanced PDAC cell tumorigenesis in vivo. Additionally, the present study demonstrated that insulin-like growth factor 2 RNA binding protein 3 (IGF2BP3) functioned as an RNA-binding protein to increase UBE2K expression by enhancing the RNA stability of UBE2K. The knockdown or overexpression of IGF2BP3 could attenuate the change in cells growth induced by the overexpression or knockdown of UBE2K. In summary, the findings indicated the oncogenic roles of UBE2K in PDAC.In addition, IGF2BP3 and UBE2K constitute a functional axis to regulate the malignant progression of PDAC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma

Lei

et al. 2023

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…The protein HIST1H2BD is expressed in myeloma cells. The use of the drug ixazomib reportedly inhibited myeloma cell growth by significantly increasing HIST1H2BD expression and reducing UBE2K expression [ 55 ]. The roles of most of the core gene-encoded proteins in DLBCL patients have not been elucidated experimentally so far [ 56 ], and could, therefore, be a focus of future investigations in this regard.…”

Section: Discussionmentioning

confidence: 99%

Identifying the Effect of COVID-19 Infection in Multiple Myeloma and Diffuse Large B-Cell Lymphoma Patients Using Bioinformatics and System Biology

Zhang

Xiao

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), also referred to as COVID-19, has spread to several countries and caused a serious threat to human health worldwide. Patients with confirmed COVID-19 infection spread the disease rapidly throughout the region. Multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) are risk factors for COVID-19, although the molecular mechanisms underlying the relationship among MM, DLBCL, and COVID-19 have not been elucidated so far. In this context, transcriptome analysis was performed in the present study to identify the shared pathways and molecular indicators of MM, DLBCL, and COVID-19, which benefited the overall understanding of the effect of COVID-19 in patients with MM and DLBCL. Three datasets (GSE16558, GSE56315, and GSE152418) were downloaded from the Gene Expression Omnibus (GEO) and searched for the shared differentially expressed genes (DEGs) in patients with MM and DLBCL who were infected with SARS-CoV-2. The objective was to detect similar pathways and prospective medicines. A total of 29 DEGs that were common across these three datasets were selected. A protein-protein interaction (PPI) network was constructed using data from the STRING database followed by the identification of hub genes. In addition, the association of MM and DLBCL with COVID-19 infection was analyzed through functional analysis using ontologies terms and pathway analysis. Three relationships were observed in the evaluated datasets: transcription factor-gene interactions, protein-drug interactions, and an integrated regulatory network of DEGs and miRNAs with mutual DEGs. The findings of the present study revealed potential pharmaceuticals that could be beneficial in the treatment of COVID-19.

show abstract

“…As a part of the post-translational protein modification, ubiquitin-proteasome system (UPS) acts as an important role in the vast majority of physiological and pathological processes including embryogenesis (23), cell growth (24), DNA damage and repair (25,26), and tumorigenesis (27,28). NEDD4L, an E3 ubiquitin ligase, has recently been identified as a tumour suppressor in many types of human cancers.…”

Section: Discussionmentioning

confidence: 99%

Peer Review #1 of "Down-regulated NEDD4L facilitates tumor progression through activating Notch signaling in lung adenocarcinoma (v0.1)"

2022

View full text Add to dashboard Cite

Ixazomib inhibits myeloma cell proliferation by targeting UBE2K

Cited by 10 publications

References 40 publications

UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma

UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma

Identifying the Effect of COVID-19 Infection in Multiple Myeloma and Diffuse Large B-Cell Lymphoma Patients Using Bioinformatics and System Biology

Peer Review #1 of "Down-regulated NEDD4L facilitates tumor progression through activating Notch signaling in lung adenocarcinoma (v0.1)"

Contact Info

Product

Resources

About